Xeltis’ devices are the first living applications of supramolecular materials for cardiovascular restoration in patients.
An article published in peer-reviewed journal Materials Today showcases how Xeltis implanted the first clinical devices made of supramolecular biomaterials to successfully restore blood vessels and heart valves in patients.
“We are extremely proud to be pioneering the clinical application of supramolecular polymers, building the first significant body of evidence on endogenous tissue restoration in clinical settings,”
explained Xeltis CTO and Co-founder Martijn Cox.
The article includes outcomes from Xeltis three world-first clinical studies, demonstrating the potential of the supramolecular UPy platform, developed by the teams working with Professor Bert Meijer and Professor Patricia Dankers at Eindhoven University of Technology, who co-authored the study.
According to the article, the development of biocompatible, biodegradable, and tuneable supramolecular biomaterials allowed unprecedented steps from laboratory to clinical studies, 30 years after the pioneering work on supramolecular assemblies by Professors Cram, Lehn and Pedersen was honored with a Nobel Prize.
